Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase

Brequinar analogs were evaluated through bioassays and in silico screening as species-specific inhibitors of dihydroorotate dehydrogenase (DHODH). A class of analogs known to not inhibit human DHODH dock well to Plasmodium falciparum DHODH. Therapeutic agents brequinar sodium and leflunomide (Arava™...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 16; no. 6; pp. 1610 - 1615
Main Authors Hurt, Darrell E., Sutton, Amanda E., Clardy, Jon
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 15.03.2006
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Brequinar analogs were evaluated through bioassays and in silico screening as species-specific inhibitors of dihydroorotate dehydrogenase (DHODH). A class of analogs known to not inhibit human DHODH dock well to Plasmodium falciparum DHODH. Therapeutic agents brequinar sodium and leflunomide (Arava™) work by binding in a hydrophobic tunnel formed by a highly variable N-terminus of family 2 dihydroorotate dehydrogenase (DHODH). The X-ray crystallographic structure of an analog of brequinar bound to human DHODH was determined. In silico screening of a library of compounds suggested another subset of brequinar analogs that do not inhibit human DHODH as potentially effective inhibitors of Plasmodium falciparum DHODH.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2005.12.029